Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
GAVRETO (PRALSETINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
GAVRETO
NDA
Get alerts
PRALSETINIB | N213721 | RIGEL PHARMACEUTICALS INC
1 strength
6 unique patents
3 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
DMF
Approvals
Label
Products
Patent Timeline
6 unique patents, 3 exclusivities by expiration date
Active (6)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
Today
10030005
Nov. 1, 2036
11273160
Apr. 3, 2039
11872192
Apr. 3, 2039
11963958
Apr. 3, 2039
12448366
Jul. 7, 2042
12539303
Apr. 3, 2039
ODE-318
Sep. 4, 2027
ODE-340
Dec. 1, 2027
ODE-341
Dec. 1, 2027
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 100MG
RLD
6 patents
3 exclusivities
▴
CAPSULE;ORAL | Approved: Sep 4, 2020
Patents (6)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10030005
Nov 1, 2036
—
Yes
Yes
U-2952
TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
—
11273160
Apr 3, 2039
—
—
—
U-2952
TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
—
11872192
Apr 3, 2039
—
—
—
U-2952
TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
—
11963958
Apr 3, 2039
—
—
—
U-2828
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
—
12448366
Jul 7, 2042
—
Yes
—
—
—
12539303
Apr 3, 2039
—
—
—
U-2828
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
—
Exclusivities (3)
Code
Date
Status
ODE-318
Sep 4, 2027
Active
ODE-340
Dec 1, 2027
Active
ODE-341
Dec 1, 2027
Active